English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Executive Summary
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.